Natacha Madelon1, Nelli Heikkilä1, Irène Sabater Royo1, Paola Fontannaz1, Gautier Breville2, Kim Lauper3, Rachel Goldstein1, Alba Grifoni4, Alessandro Sette4,5, Claire-Anne Siegrist1,6, Axel Finckh3, Patrice H Lalive2, Arnaud M Didierlaurent1, Christiane S Eberhardt1,6,7. 1. Faculty of Medicine, Center for Vaccinology, Department of Pathology and Immunology, University of Geneva, Geneva, Switzerland. 2. Division of Neurology, Department of Neurosciences, University Hospital of Geneva, Faculty of Medicine, University of Geneva, Geneva, Switzerland. 3. Division of Rheumatology, Department of Medicine, University Hospital of Geneva, Faculty of Medicine, University of Geneva, Geneva, Switzerland. 4. Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, University of California, San Diego, La Jolla. 5. Division of Infectious Diseases and Global Public Health, Department of Medicine, University of California, San Diego, La Jolla. 6. Division of General Pediatrics, Department of Woman, Child and Adolescent Medicine, Faculty of Medicine, University of Geneva, Center for Vaccinology, Geneva University Hospitals, Geneva, Switzerland. 7. Emory Vaccine Center, Emory University School of Medicine, Atlanta, Georgia.
Abstract
IMPORTANCE: The SARS-CoV-2 variant B.1.1.529 (Omicron) escapes neutralizing antibodies elicited after COVID-19 vaccination, while T-cell responses might be better conserved. It is crucial to assess how a third vaccination modifies these responses, particularly for immunocompromised patients with readily impaired antibody responses. OBJECTIVE: To determine T-cell responses to the Omicron spike protein in anti-CD20-treated patients with multiple sclerosis (MS) before and after a third messenger RNA COVID-19 vaccination. DESIGN, SETTING, AND PARTICIPANTS: In this prospective cohort study conducted from March 2021 to November 2021 at the University Hospital Geneva, adults with MS receiving anti-CD20 treatment (ocrelizumab) were identified by their treating neurologists and enrolled in the study. A total of 20 patients received their third dose of messenger RNA COVID-19 vaccine and were included in this analysis. INTERVENTIONS: Blood sampling before and 1 month after the third vaccine dose. MAIN OUTCOMES AND MEASURES: Quantification of CD4 and CD8 (cytotoxic) T cells specific for the SARS-CoV-2 spike proteins of the vaccine strain as well as the Delta and Omicron variants, comparing frequencies before and after the third vaccine dose. RESULTS: Of 20 included patients, 11 (55%) were male, and the median (IQR) age was 45.8 (37.8-53.3) years. Spike-specific CD4 and CD8 T-cell memory against all variants were maintained in 9 to 12 patients 6 months after their second vaccination, albeit at lower median frequencies against the Delta and Omicron variants compared with the vaccine strain (CD8 T cells: Delta, 83.0%; 95% CI, 73.6-114.5; Omicron, 78.9%; 95% CI, 59.4-100.0; CD4 T cells: Delta, 72.2%; 95% CI, 67.4-90.5; Omicron, 62.5%; 95% CI, 51.0-89.0). A third dose enhanced the number of responders to all variants (11 to 15 patients) and significantly increased CD8 T-cell responses, but the frequencies of Omicron-specific CD8 T cells remained 71.1% (95% CI, 41.6-96.2) of the responses specific to the vaccine strain. CONCLUSIONS AND RELEVANCE: In this cohort study of patients with MS treated with ocrelizumab, there were robust T-cell responses recognizing spike proteins from the Delta and Omicron variants, suggesting that COVID-19 vaccination in patients taking B-cell-depleting drugs may protect them against serious complications from COVID-19 infection. T-cell response rates increased after the third dose, demonstrating the importance of a booster dose for this population.
IMPORTANCE: The SARS-CoV-2 variant B.1.1.529 (Omicron) escapes neutralizing antibodies elicited after COVID-19 vaccination, while T-cell responses might be better conserved. It is crucial to assess how a third vaccination modifies these responses, particularly for immunocompromised patients with readily impaired antibody responses. OBJECTIVE: To determine T-cell responses to the Omicron spike protein in anti-CD20-treated patients with multiple sclerosis (MS) before and after a third messenger RNA COVID-19 vaccination. DESIGN, SETTING, AND PARTICIPANTS: In this prospective cohort study conducted from March 2021 to November 2021 at the University Hospital Geneva, adults with MS receiving anti-CD20 treatment (ocrelizumab) were identified by their treating neurologists and enrolled in the study. A total of 20 patients received their third dose of messenger RNA COVID-19 vaccine and were included in this analysis. INTERVENTIONS: Blood sampling before and 1 month after the third vaccine dose. MAIN OUTCOMES AND MEASURES: Quantification of CD4 and CD8 (cytotoxic) T cells specific for the SARS-CoV-2 spike proteins of the vaccine strain as well as the Delta and Omicron variants, comparing frequencies before and after the third vaccine dose. RESULTS: Of 20 included patients, 11 (55%) were male, and the median (IQR) age was 45.8 (37.8-53.3) years. Spike-specific CD4 and CD8 T-cell memory against all variants were maintained in 9 to 12 patients 6 months after their second vaccination, albeit at lower median frequencies against the Delta and Omicron variants compared with the vaccine strain (CD8 T cells: Delta, 83.0%; 95% CI, 73.6-114.5; Omicron, 78.9%; 95% CI, 59.4-100.0; CD4 T cells: Delta, 72.2%; 95% CI, 67.4-90.5; Omicron, 62.5%; 95% CI, 51.0-89.0). A third dose enhanced the number of responders to all variants (11 to 15 patients) and significantly increased CD8 T-cell responses, but the frequencies of Omicron-specific CD8 T cells remained 71.1% (95% CI, 41.6-96.2) of the responses specific to the vaccine strain. CONCLUSIONS AND RELEVANCE: In this cohort study of patients with MS treated with ocrelizumab, there were robust T-cell responses recognizing spike proteins from the Delta and Omicron variants, suggesting that COVID-19 vaccination in patients taking B-cell-depleting drugs may protect them against serious complications from COVID-19 infection. T-cell response rates increased after the third dose, demonstrating the importance of a booster dose for this population.
Authors: Natacha Madelon; Kim Lauper; Gautier Breville; Irène Sabater Royo; Rachel Goldstein; Diego O Andrey; Alba Grifoni; Alessandro Sette; Laurent Kaiser; Claire Anne Siegrist; Axel Finckh; Patrice H Lalive; Arnaud M Didierlaurent; Christiane S Eberhardt Journal: Clin Infect Dis Date: 2022-08-24 Impact factor: 20.999
Authors: Rishi R Goel; Mark M Painter; Sokratis A Apostolidis; Divij Mathew; Wenzhao Meng; Aaron M Rosenfeld; Kendall A Lundgreen; Arnold Reynaldi; David S Khoury; Ajinkya Pattekar; Sigrid Gouma; Leticia Kuri-Cervantes; Philip Hicks; Sarah Dysinger; Amanda Hicks; Harsh Sharma; Sarah Herring; Scott Korte; Amy E Baxter; Derek A Oldridge; Josephine R Giles; Madison E Weirick; Christopher M McAllister; Moses Awofolaju; Nicole Tanenbaum; Elizabeth M Drapeau; Jeanette Dougherty; Sherea Long; Kurt D'Andrea; Jacob T Hamilton; Maura McLaughlin; Justine C Williams; Sharon Adamski; Oliva Kuthuru; Ian Frank; Michael R Betts; Laura A Vella; Alba Grifoni; Daniela Weiskopf; Alessandro Sette; Scott E Hensley; Miles P Davenport; Paul Bates; Eline T Luning Prak; Allison R Greenplate; E John Wherry Journal: Science Date: 2021-12-03 Impact factor: 63.714
Authors: Alison Tarke; Camila H Coelho; Zeli Zhang; Jennifer M Dan; Esther Dawen Yu; Nils Methot; Nathaniel I Bloom; Benjamin Goodwin; Elizabeth Phillips; Simon Mallal; John Sidney; Gilberto Filaci; Daniela Weiskopf; Ricardo da Silva Antunes; Shane Crotty; Alba Grifoni; Alessandro Sette Journal: Cell Date: 2022-01-24 Impact factor: 41.582
Authors: Wilfredo F Garcia-Beltran; Kerri J St Denis; Angelique Hoelzemer; Evan C Lam; Adam D Nitido; Maegan L Sheehan; Cristhian Berrios; Onosereme Ofoman; Christina C Chang; Blake M Hauser; Jared Feldman; Alex L Roederer; David J Gregory; Mark C Poznansky; Aaron G Schmidt; A John Iafrate; Vivek Naranbhai; Alejandro B Balazs Journal: Cell Date: 2022-01-06 Impact factor: 41.582
Authors: Sachin P Gadani; Maria Reyes-Mantilla; Larissa Jank; Samantha Harris; Morgan Douglas; Matthew D Smith; Peter A Calabresi; Ellen M Mowry; Kathryn C Fitzgerald; Pavan Bhargava Journal: EBioMedicine Date: 2021-10-16 Impact factor: 8.143
Authors: Sokratis A Apostolidis; Mihir Kakara; Mark M Painter; Rishi R Goel; Divij Mathew; Kerry Lenzi; Ayman Rezk; Kristina R Patterson; Diego A Espinoza; Jessy C Kadri; Daniel M Markowitz; Clyde E Markowitz; Ina Mexhitaj; Dina Jacobs; Allison Babb; Michael R Betts; Eline T Luning Prak; Daniela Weiskopf; Alba Grifoni; Kendall A Lundgreen; Sigrid Gouma; Alessandro Sette; Paul Bates; Scott E Hensley; Allison R Greenplate; E John Wherry; Rui Li; Amit Bar-Or Journal: Nat Med Date: 2021-09-14 Impact factor: 53.440
Authors: Alison Tarke; John Sidney; Nils Methot; Esther Dawen Yu; Yun Zhang; Jennifer M Dan; Benjamin Goodwin; Paul Rubiro; Aaron Sutherland; Eric Wang; April Frazier; Sydney I Ramirez; Stephen A Rawlings; Davey M Smith; Ricardo da Silva Antunes; Bjoern Peters; Richard H Scheuermann; Daniela Weiskopf; Shane Crotty; Alba Grifoni; Alessandro Sette Journal: Cell Rep Med Date: 2021-07-02
Authors: Thomas Marjot; Christiane S Eberhardt; Tobias Boettler; Luca S Belli; Marina Berenguer; Maria Buti; Rajiv Jalan; Mario U Mondelli; Richard Moreau; Daniel Shouval; Thomas Berg; Markus Cornberg Journal: J Hepatol Date: 2022-07-20 Impact factor: 30.083
Authors: Martin S Weber; Mathias Buttmann; Sven G Meuth; Petra Dirks; Erwan Muros-Le Rouzic; Julius C Eggebrecht; Stefanie Hieke-Schulz; Jost Leemhuis; Tjalf Ziemssen Journal: Front Neurol Date: 2022-05-09 Impact factor: 4.086
Authors: Virginia Palomares Cabeza; Laura Y L Kummer; Luuk Wieske; Ruth R Hagen; Mariel Duurland; Veronique A L Konijn; Koos P J van Dam; Eileen W Stalman; Carolien E van de Sandt; Laura Boekel; Niels J M Verstegen; Maurice Steenhuis; Theo Rispens; Sander W Tas; Gertjan Wolbink; Joep Killestein; Taco W Kuijpers; S Marieke van Ham; Filip Eftimov; Anja Ten Brinke; Zoé L E van Kempen Journal: Neurol Neuroimmunol Neuroinflamm Date: 2022-05-06
Authors: Alison Tarke; Camila H Coelho; Zeli Zhang; Jennifer M Dan; Esther Dawen Yu; Nils Methot; Nathaniel I Bloom; Benjamin Goodwin; Elizabeth Phillips; Simon Mallal; John Sidney; Gilberto Filaci; Daniela Weiskopf; Ricardo da Silva Antunes; Shane Crotty; Alba Grifoni; Alessandro Sette Journal: Cell Date: 2022-01-24 Impact factor: 41.582
Authors: Eloise Phillips; Sandra Adele; Tom Malone; Alexandra Deeks; Lizzie Stafford; Susan L Dobson; Ali Amini; Donal Skelly; David Eyre; Katie Jeffery; Christopher P Conlon; Christina Dold; Ashley Otter; Silvia D'Arcangelo; Lance Turtle; Paul Klenerman; Eleanor Barnes; Susanna J Dunachie Journal: Clin Exp Immunol Date: 2022-07-22 Impact factor: 5.732